New pertussis vaccination approaches: En route to protect newborns?

FEMS Immunology and Medical Microbiology

Volumn 66, Issue 2, 2012, Pages 121-133

  Locht, Camille ^a,b,c   Mielcarek, Nathalie ^a,b,c  

^a INSTITUT PASTEUR DE LILLE   (France)

^b INSERM U1019   (France)

^c UNIV LILLE   (France)

Author keywords

Nasal immunization; Neonatal protection; Pertussis; Vaccine

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ; MATERNAL ANTIBODY; PERTUSSIS TOXIN; PERTUSSIS VACCINE; PLACEBO;

ANOREXIA; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BORDETELLA PERTUSSIS; BRAIN DAMAGE; BRAIN DISEASE; CELLULAR IMMUNITY; CHILD DEATH; CRYING; DIPHTHERIA; DROWSINESS; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG SAFETY; FEBRILE CONVULSION; FEVER; GROUPS BY AGE; HEPATITIS B; HIGH RISK INFANT; HUMAN; IMMUNIZATION; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MEMBRANE VESICLE; MUCOSAL IMMUNITY; MUSCLE HYPOTONIA; NEWBORN; NONHUMAN; PATIENT COMPLIANCE; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; TETANUS; VACCINATION; VACCINATION REACTION;

ADOLESCENT; BIOMEDICAL RESEARCH; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PERTUSSIS VACCINE; PREGNANCY; VACCINATION; VACCINES, ACELLULAR; VACCINES, ATTENUATED; VACCINES, INACTIVATED; WHOOPING COUGH;

EID: 84867732573     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2012.00988.x     Document Type: Short Survey

References (95)

1. Ad Hoc Group for the Study of Pertussis Vaccines (1988) Placebo-controlled trial of two acellular pertussis vaccines in Sweden - protective efficacy and adverse events. Lancet 1: 955-960.
2. Alvarez Hayes J, Erben E, Lamberti Y, Ayala M, Maschi F, Carbone C, Gatti B, Parisi G & Rodriguez ME (2011) Identification of a new protective antigen of Bordetella pertussis. Vaccine 29: 8731-9739.
3. Asensio CJA, Gaillard ME, Moreno G, Bottero D, Zurita E, Rumbo M, van der Ley P, van der Ark A & Hozbor D (2011) Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine 29: 1649-1656.
4. Baker JP (2003) The pertussis vaccine controversy in Great Britain, 1974-1986. Vaccine 21: 4003-4010.
5. Baumann E, Binder BR, Falk W, Huber EG, Kurz R & Rosanelli K (1985) Development and clinical use of an oral heat-inactivated whole cell pertussis vaccine. Dev Biol Stand 61: 511-516.
6. Belloni C, De Silvestri A, Tinelli C, Avanzini MA, Marconi M, Strano F, Rondini G & Chirico G (2003) Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 111: 1042-1045.
7. Berstad AKH, Holst J, Froholm LO, Haugen IL, Wedege E, Oftung F & Haneberg B (2000a) A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. J Med Microbiol 49: 157-163.
8. Berstad AKH, Oftung F, Korsvold GE, Haugen IL, Froholm LO, Holst J & Haneberg B (2000b) Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine. Vaccine 18: 2323-2330.
9. Bey RF, Shade FJ, Goodnow RA & Johnson RC (1981) Intranasal vaccination of dogs with live avirulent Bordetella bronchiseptica: correlation of serum agglutination titer and the formation of secretory IgA in protection against experimentally induced infectious tracheobronchitis. Am J Vet Res 42: 1130-1132.
10. Bisgard KM, Pascual FB, Ehresmann KR, Miller CA, Cianfrini C, Jennings CE, Rebmann CA, Gabel J, Schauer SL & Lett SM (2004) Infant pertussis: who was the source? Pediatr Infect Dis J 23: 985-989.
11. Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP & Ehresmann KR (2005) Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics 83: 369-374.
12. Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E & Guiso N (2009) First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine 27: 6034-6041.
13. Cheung GYC, Xing D, Prior S, Gorbel MJ, Parton R & Coote JG (2006) Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model. Infect Immun 74: 6797-6805.
14. Cohn SE, Knorr KI, Gilligan PH, Smiley ML & Weber DJ (1993) Pertussis is rare in human immunodeficiency virus disease. Am Rev Respir Dis 147: 411-413.
15. Davis SS (2001) Nasal vaccines. Adv Drug Deliv Rev 51: 21-42.
16. De la Rocque F, Grimprel E, Gaudelus J, Lécuyer A, Wollner C, Leroux MC & Cohen R (2007) Vaccination in parents of young infants survey. Arch Pediatr 14: 1472-1476.
17. DeMaria A Jr & Lett SM (2010) Vaccinate the village. Clin Infect Dis 50: 1346-1348.
18. Feunou PF, Ismaili J, Debrie AS, Huot L, Hot D, Raze D, Lemoine Y & Locht C (2008) Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine 26: 5722-5727.
19. Feunou PF, Bertout J & Locht C (2010a) T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis. PLoS ONE 5: e10178.
20. Feunou PF, Kammoun H, Debrie AS, Mielcarek N & Locht C (2010b) Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine 28: 7047-7053.
21. Fine PE & Clarkson JA (1987) Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 9: 866-883.
22. Forsyth K, von König CW, Tan T, Caro J & Plotkin S (2007) Prevention of pertussis: recommendations derived from the second global pertussis initiative roundtable meeting. Vaccine 25: 2634-2642.
23. Garlapati S, Eng NF, Kiros TG, Kindrachuk J, Mutwiri GK, Hancock RE, Halperin SA, Potter AA, Babiuk LA & Gerdts V (2011) Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. Vaccine 29: 6540-6548.
24. Gordon J & Hood R (1951) Whooping cough and its epidemiological anomalies. Prev Med Epidemiol 222: 333-361.
25. Gracia A, Polewicz M, Halperin SA, Hancock RE, Potter AA, Babiuk LA & Gerdts V (2011) Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations. Vaccine 29: 1595-1604.
26. Greco D, Salmaso S, Mastrantonio P et al. (1996) A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 334: 341-348.
27. Grimpel E, von Sonnenburg F, Saenger R, Abitbol V, Wolter J & Schuerman L (2005) Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine 23: 3657-3667.
28. Guiso N, Szatanik M & Rocancourt M (1991) Protective activity of Bordetella adenylate cyclase-hemolysin against bacterial colonization. Microb Pathog 11: 423-431.
29. Gustafsson L, Hallander HO, Olin P, Reizenstein E & Storsaeter J (1996) A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334: 349-355.
30. Gustafsson L, Hessel L, Storsaeter J & Olin P (2006) Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5 and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 118: 978-984.
31. Haberling DL, Holman RC, Paddock CD & Murphy TV (2009) Infant and maternal risk factors for pertussis-related infant mortality in the United States, 1999 to 2004. Pediatr Infect Dis J 28: 194-198.
32. Halasa NB, O'Shea A, Shi JR, LaFleur BJ & Edwards KM (2008) Poor immune responses to a birth dose of diphtheria, tetanus and acellular pertussis vaccine. J Pediatr 153: 327-332.
33. Hale C, Humphreys IR, Hussell T, Bowe F, Clare S, Pickard D, Preston A, Del Giudice G & Dougan G (2004) Mucosal immunization of murine neonates using whole cell and acellular pertussis vaccines. Vaccine 22: 3595-3602.
34. Hallander HO, Nilsson L & Gustafsson L (2011) Is adolescent pertussis vaccination preferable to natural booster infections? Expert Rev Clin Pharmacol 4: 705-711.
35. Healy CM, Rench MA & Baker CJ (2011) Implementation of cocooning against pertussis in a high-risk population. Clin Infect Dis 52: 157-162.
36. Heijbel H, Rasmussen F & Olin P (1997) Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II. Dev Biol Stand 89: 99-100.
37. Hellwig SM, van Spriel AB, Schellekens JF, Mooi FR & van de Winkel JG (2001) Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infect Immun 69: 4846-4850.
38. Higginson D, Theodoratou E, Nair H, Huda T, Zgaga L, Jadhav SS, Omer SB, Rudan I & Campbell H (2011) An evaluation of respiratory administration of measles vaccine for prevention of acute lower respiratory infections in children. BMC Public Health 11(suppl 3): S31.
39. Howson CP, Howe CJ & Fineberg HV (1991) Adverse Effects of Pertussis and Rubella Vaccines. National Academy Press, Washington, DC.
40. Huang CC, Chen PM, Kuo JK, Chui WH, Lin ST, Lin HS & Lin YC (1962) Experimental whooping cough. N Engl J Med 266: 105-111.
41. Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS & Illum L (1998) Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 16: 2039-2046.
42. Kavanagh H, Noone C, Cahill E, English K, Locht C & Mahon BP (2010) Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model. Clin Exp Allergy 40: 933-941.
43. Kendrick P, Thompson M & Eldering G (1945) Immunity response of mothers and babies to injections of pertussis vaccine during pregnancy. Am J Dis Child 70: 25-28.
44. Kendrick PL, Eldering G, Dixon MK & Misner J (1947) Mouse protection tests in the study of pertussis vaccine: a comparative series using the intracerebral route for challenge. Am J Public Health 37: 803-810.
45. Knuf M, Schmitt HJ, Wolter J, Schuerman L, Jacquet JM, Kieninger D, Siegrist CA & Zepp F (2008) Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 152: 655-660.
46. Knuf M, Schmitt HJ, Jacquet JM, Collard A, Kieninger D, Meyer CU, Siegrist CA & Zepp F (2010) Booster vaccination after neonatal priming with acellular pertussis vaccine. J Pediatr 156: 675-678.
47. Kuehn BM (2010) Panel backs wider pertussis vaccination to curb outbreaks, prevent deaths. JAMA 304: 2684-2686.
48. Lavine J, Broutin H, Harvill ET & Bjornstad ON (2010) Imperfect vaccine-induced immunity and whooping cough transmission to infants. Vaccine 29: 11-16.
49. Lavine JS, Bjornstad ON, Freiesleben de Blasio B & Storsaeter J (2012) Short-lived immunity against pertussis, age-specific routes of transmission and the utility of a teenage booster vaccine. Vaccine 30: 544-551.
50. Lee SF, Halperin SA, Salloum DF, MacMillan A & Morris A (2003) Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein. Infect Immun 71: 2272-2275.
51. Lee GM, Lett S, Schauer S, LeBaron C, Murphy TV, Rusinak D, Lieu TA & Massachusetts Pertussis Study Group (2004) Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis 39: 1572-1580.
52. Levine MM (2003) Can needle-free administration of vaccines become the norm in global immunization? Nat Med 9: 99-103.
53. Lewis R (2011) Updated recommendations for Tdap include pregnant women. MMWR Morb Mortal Wkly Rep 60: 1424-1426.
54. Li R, Lim A, Phoon MC, Narasaraju T, Ng JKW, Poh WP, Sim MK, Chow VT, Locht C & Alonso S (2010) Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm. J Virol 84: 7105-7113.
55. Locht C (2008) A common vaccination strategy to sole unsolved problems of tuberculosis and pertussis? Microbes Infect 10: 1051-1056.
56. Luman ET, McCauley MM, Stokley S, Chu SY & Pickering LK (2002) Timelines of childhood immunizations. Pediatrics 110: 935-939.
57. MacDonald-Fyall J, Xing D, Corbel MJ, Baillie S, Parton R & Coote J (2004) Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens. Vaccine 22: 4270-4281.
58. Mahon BP, Sheahan BJ, Griffin F, Murphy G & Mills KHG (1997) Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin μ chain genes. J Exp Med 186: 1843-1851.
59. Marr N, Oliver DC, Laurent V, Poolman J, Denoël P & Fernandez RC (2008) Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model. Vaccine 26: 4306-4311.
60. Mascart F, Verscheure V, Malfroot A et al. (2003) Bordetella pertussis infection in 2-months-old infants promotes type 1 T cell responses. J Immunol 170: 1504-1509.
61. Medical Research Council (1951) The prevention of whooping cough by vaccination. Br Med J 1: 1463-1471.
62. Medical Research Council (1956) Vaccination against whooping cough: relation between protection in children and results of laboratory tests. Br Med J 2: 454-462.
63. Mielcarek N, Alonso S & Locht C (2001) Nasal vaccination using live bacterial vectors. Adv Drug Deliv Rev 51: 55-69.
64. Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, Ben Younes A, Creusy C, Engle J, Goldman WE & Locht C (2006) Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2: e65.
65. Mielcarek N, Debrie AS, Mahieux S & Locht C (2010) Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin Vaccine Immunol 17: 317-324.
66. Mills KHG, Ryan M, Ryan E & Mahon BP (1998) A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 66: 594-602.
67. Mooi FR (2010) Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect Genet Evol 10: 36-49.
68. Mooi FR & De Greeff SC (2007) The case for maternal vaccination against pertussis. Lancet Infect Dis 7: 614-624.
69. Mossong J, Hens N, Jit M et al. (2008) Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 5: e74.
70. Mutch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C & Steffen R (2004) Use of inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350: 896-903.
71. Polewicz M, Gracia A, Buchanan R, Strom S, Halperin SA, Potter AA, Babiuk LA & Gerdts V (2011) Influence of maternal antibodies on active pertussis toxoid immunization of neonatal mice and piglets. Vaccine 29: 7718-7726.
72. Provenzano RW, Wetterlow LH & Sullivan CL (1965) Immunization and antibody response in the newborn infant, I. pertussis inoculation within twenty-four hours of birth. N Engl J Med 273: 959-965.
73. Rennels MB (2003) Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis 14: 196-198.
74. Roberts M, Maskell D, Novotny P & Dougan G (1990) Construction and characterization in vivo of Bordetella pertussis aroA mutants. Infect Immun 58: 732-739.
75. Roduit C, Bozzotti P, Mielcarek N, Lambert PH, del Giudice G, Locht C & Siegrist CA (2002) Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis. Infect Immun 70: 3521-3528.
76. Rohani P, Zhong X & King AA (2010) Contact network structure explains the changing epidemiology of pertussis. Science 330: 982-985.
77. Sato Y, Kimura M & Fukumi H (1984) Development of a pertussis component vaccine in Japan. Lancet 1: 122-126.
78. Shim DH, Ko HJ, Volker G, Potter AA, Mutwiri G, Babiuk LA & Kweon MN (2010) Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens. Vaccine 28: 2311-2317.
79. Skerry CM & Mahon BP (2011) A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. Clin Vaccine Immunol 18: 187-193.
80. Skerry CM, Cassidy JP, English K, Feunou Feunou P, Locht C & Mahon BP (2009) A live attenuated Bordetella pertussis candidate vaccine does not cause disseminated infection in gamma interferon receptor knockout mice. Clin Vaccine Immunol 16: 1344-1351.
81. Skowronski DM, Janjua NZ, Tsafack EPS, Ouakki M, Hoang L & De Serres G (2012) The number needed to vaccinate to prevent infant pertussis hospitalization and death through parent cocoon immunization. Clin Infect Dis 54: 318-327.
82. Storsaeter J, Wolter J & Locht C (2007) Pertussis vaccines. Bordetella Molecular Microbiology (Locht C, ed), pp. 245-288. Horizon Press, Norfolk, UK.
83. Sugai T, Mori M, Nakazawa M, Ichino M, Naruto T, Kobayashi N, Kobayashi Y, Minami M & Yokota S (2005) A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine. Vaccine 23: 5450-5456.
84. Thomas G (1975) Respiratory and humoral immune response to aerosol and intramuscular pertussis vaccine. J Hyg 74: 233-237.
85. Troseid M, Jonassen TO & Steinbakk M (2006) Isolation of Bordetella pertussis in blood culture from a patient with multiple myeloma. J Infect 52: e11-e13.
86. Van Rie A, Wendelboe AM & Englund JA (2005) Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J 24: S62-S65.
87. Von König CH, Halperin SA, Riffelmann M & Guiso N (2002) Pertussis of adults and infants. Lancet Infect Dis 2: 744-750.
88. Waruiru C & Appelton R (2004) Febrile seizures: an update. Arch Dis Child 89: 751-756.
89. Watanabe N & Nagai M (2001) Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection. Infect Immun 69: 6981-6986.
90. Wearing HJ & Rohani P (2009) Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathog 5: e1000657.
91. Wendelboe AM, Van Rie A, Salmaso S & Englund JA (2005) Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 24(5 suppl): S58-S61.
92. White OJ, Rowe J, Richmond P, Marshall H, McIntyre P, Wood N & Holt PG (2010) Th-2 polarisation of cellular immune memory to neonatal pertussis vaccination. Vaccine 28: 2648-2652.
93. WHO (2011) Global routine vaccination coverage 2010. Wkly Epidemiol Rec 86: 509-520.
94. Wood N, McIntyre P, Marshall H & Roberton D (2010) Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J 29: 209-215.
95. Zorzeto TQ, Higashi HG, da Silva MT et al. (2009) Immunogenicity of a whole-cell pertussis vaccine with low lipopolysaccharide content in infants. Clin Vaccine Immunol 16: 544-550.